What is Qualigen Therapeutics Inc's earnings per share (EPS)?

Qualigen Therapeutics Inc (QLGN) reported diluted earnings per share of -$8.11 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Qualigen Therapeutics Inc Financials

QLGN

FY2025 annual

Revenue Not reported for FY2025

Net Income -$17.0M -171.1% YoY

EPS (Diluted) -$8.11 YoY not available

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Qualigen Therapeutics Inc (QLGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI QLGN FY2025 2026-08-15

Qualigen’s stronger FY2025 balance sheet was built by external financing, while operating losses still outweighed any self-funded progress.

Across the last three valid years, solvency improved faster than operations: equity swung from negative to $28.0M even though net losses continued and operating cash remained negative. The cleaner balance sheet is therefore a recapitalization story, with financing cash of $41.0M more than covering FY2025 operating cash flow of -$7.0M.

R&D fell from $5.2M to $185K over two years, showing the cost base has moved away from active research. With SG&A still at $8.8M, overhead now dominates spending, so losses look tied more to maintaining the corporate structure than to expanding development work.

The company now carries a cash-heavy, lightly levered balance sheet, with $19.3M of cash versus $3.3M of total liabilities. But FY2025 operating cash flow of -$7.0M means that liquidity reflects capital raised, not cash produced by the business, and still depends on outside funding to absorb ongoing cash use.

Financial Health Signals

Financial health score not available

Qualigen Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Qualigen Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Qualigen Therapeutics Inc reported a net loss of $17.0M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Qualigen Therapeutics Inc reported an operating loss of $13.2M against $989K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$17.0M

YoY-171.1%

Qualigen Therapeutics Inc reported -$17.0M in net income in fiscal year 2025. This represents a decrease of 171.1% from the prior year.

EPS (Diluted)

-$8.11

Qualigen Therapeutics Inc earned -$8.11 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$19.3M

YoY+1545.9%

5Y CAGR-4.2%

10Y CAGR+2.0%

Qualigen Therapeutics Inc held $19.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Qualigen Therapeutics Inc had 5M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-60.7%

YoY+172.9pp

Qualigen Therapeutics Inc's ROE was -60.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 172.9 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$185K

YoY-84.6%

Qualigen Therapeutics Inc invested $185K in research and development in fiscal year 2025. This represents a decrease of 84.6% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

QLGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

QLGN annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	N/A	N/A	N/A	$5.0M-11.9%	$5.7M+31.3%	$4.3M	$5.6M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$113K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$689K+9.5%	$630K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$185K-84.6%	$1.2M-77.0%	$5.2M+16.1%	$4.5M-61.7%	$11.7M	N/A	$6.1M	$12.3M+326.6%	$2.9M-78.4%	$13.3M+488.1%	$2.3M+1883.9%	$114K
SG&A Expenses	N/A	$8.8M+109.8%	$4.2M-31.0%	$6.1M-40.7%	$10.3M-12.4%	$11.7M	N/A	$4.6M	$5.4M+13.5%	$4.8M-2.1%	$4.9M-23.8%	$6.4M+225.1%	$2.0M
Operating Income	N/A	-$13.2M-129.1%	-$5.8M	N/A	-$14.8M+34.9%	-$22.7M	N/A	-$10.8M	-$17.9M-126.4%	-$7.9M+57.2%	-$18.4M-107.1%	-$8.9M-290.4%	-$2.3M
Interest Expense	N/A	$989K+8.8%	$909K-40.4%	$1.5M+4532.7%	-$34K-180.6%	$43K	N/A	$283K	N/A	N/A	N/A	N/A	$10K
Income Tax	N/A	$0-100.0%	$6K+232.2%	-$5K-173.2%	$7K+20.7%	$5K	N/A	$4K	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$17.0M-171.1%	-$6.3M	N/A	-$18.6M-4.2%	-$17.9M+12.4%	-$20.4M	-$10.1M	-$16.9M-114.5%	-$7.9M+57.2%	-$18.4M-109.2%	-$8.8M-255.3%	-$2.5M
EPS (Diluted)	—	-$8.11	-$17.55	-$132.25	-$3.62	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
R&D Expenses	$5K	N/A	$106K+492.6%	$18K-46.3%	$33K	N/A	$123K-83.6%	$754K
SG&A Expenses	$3.5M	N/A	$1.9M+35.6%	$1.4M-44.1%	$2.5M	N/A	$1.1M+16.1%	$986K
Operating Income	-$4.3M	N/A	-$1.4M+15.1%	-$1.7M+38.2%	-$2.7M	N/A	-$1.3M+27.1%	-$1.7M
Interest Expense	N/A	N/A	$342K+222.7%	$106K+44.1%	$74K	N/A	$28K-89.4%	$264K
Income Tax	$0	N/A	N/A	N/A	$35	N/A	-$2K-81.4%	-$1K
Net Income	-$6.1M	N/A	-$2.0M-20.9%	-$1.7M+36.3%	-$2.6M	N/A	-$1.8M-13.8%	-$1.6M
EPS (Diluted)	-$0.79	N/A	-$4.68	-$1.00+45.1%	-$1.82	N/A	-$4.70	-$10.37

TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

No annual filing on record for: FY2019.

QLGN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

QLGN annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Total Assets	$31.3M+567.4%	$4.7M+130.5%	$2.0M-89.3%	$19.1M-16.4%	$22.8M-21.6%	$29.1M	$3.7M	$15.3M-32.9%	$22.8M+215.5%	$7.2M-54.9%	$16.0M+441.3%	$3.0M
Current Assets	$31.0M+560.8%	$4.7M+301.5%	$1.2M-89.2%	$10.8M-48.0%	$20.8M-26.3%	$28.2M	$1.6M	$15.3M-33.0%	$22.8M+216.5%	$7.2M-55.0%	$16.0M+470.8%	$2.8M
Cash & Equivalents	$19.3M+1545.9%	$1.2M+192.3%	$402K-94.3%	$7.0M-23.3%	$9.2M-61.7%	$24.0M	$153K	$7.8M-65.5%	$22.6M+221.2%	$7.0M-55.5%	$15.8M+475.8%	$2.7M
Inventory	N/A	N/A	N/A	$1.6M+50.2%	$1.1M+10.7%	$953K	$660K	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$539K0.0%	$539K-34.5%	$822K+33.6%	$616K	$417K	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$626K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M+65.8%	$2.0M-51.5%	$4.1M-59.9%	$10.3M+64.5%	$6.3M-42.1%	$10.8M	$5.6M	$5.9M+119.1%	$2.7M-12.7%	$3.1M+128.8%	$1.4M-92.2%	$17.5M
Current Liabilities	$3.3M+65.8%	$2.0M-51.5%	$4.1M-51.9%	$8.6M+85.7%	$4.6M-55.6%	$10.4M	$5.3M	$5.9M+119.1%	$2.7M-13.6%	$3.1M+131.3%	$1.4M+8.0%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$139K	$2.2M	N/A	N/A	N/A	N/A	N/A
Total Equity	$28.0M+943.3%	$2.7M+227.4%	-$2.1M-129.1%	$7.2M-56.3%	$16.6M-9.5%	$18.3M	-$1.9M	$9.4M-53.4%	$20.1M+386.5%	$4.1M-71.8%	$14.7M+201.3%	-$14.5M
Retained Earnings	-$140.0M-13.8%	-$123.1M-5.4%	-$116.8M-13.0%	-$103.4M-22.0%	-$84.7M-26.8%	-$66.8M	-$47.3M	-$70.2M-31.6%	-$53.3M-17.3%	-$45.5M-67.9%	-$27.1M-51.3%	-$17.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$23.9M-23.6%	$31.3M-28.0%	$43.5M+997.0%	$4.0M+39.2%	$2.8M-39.2%	$4.7M+102.6%	$2.3M+332.8%	$534K
Current Assets	$23.5M-24.1%	$31.0M-28.8%	$43.5M+997.5%	$4.0M+39.2%	$2.8M-39.3%	$4.7M+102.5%	$2.3M+332.8%	$534K
Cash & Equivalents	$6.2M-67.9%	$19.3M-50.1%	$38.8M+11593.9%	$332K+997.7%	$30K-97.4%	$1.2M+202.6%	$388K+227.0%	$119K
Total Liabilities	$2.0M-39.0%	$3.3M-32.4%	$4.9M-12.3%	$5.6M+99.5%	$2.8M+40.2%	$2.0M-54.9%	$4.5M-7.4%	$4.8M
Current Liabilities	$2.0M-39.0%	$3.3M-32.4%	$4.9M-12.3%	$5.6M+99.5%	$2.8M+40.2%	$2.0M-54.9%	$4.5M-7.4%	$4.8M
Total Equity	$21.9M-21.7%	$28.0M-27.5%	$38.5M+2433.0%	-$1.7M-5086.7%	$33K-98.8%	$2.7M+225.1%	-$2.1M+50.0%	-$4.3M
Retained Earnings	-$146.1M-4.3%	-$140.0M-8.2%	-$129.4M-1.6%	-$127.4M-1.3%	-$125.7M-2.2%	-$123.1M-0.7%	-$122.2M-1.5%	-$120.4M

No annual filing on record for: FY2019.

QLGN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

QLGN annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$9.9M	-$7.0M-9.9%	-$6.3M	N/A	-$13.2M+10.1%	-$14.7M	N/A	-$14.5M	-$13.3M-80.2%	-$7.4M+51.4%	-$15.2M-165.8%	-$5.7M-394.4%	-$1.2M
Capital Expenditures	N/A	N/A	N/A	N/A	$165K+22.5%	$134K	N/A	$2K	$2K-73.8%	$8K-4.8%	$8K-52.6%	$17K+1357.9%	$1K
Free Cash Flow	N/A	N/A	N/A	N/A	-$13.4M+9.8%	-$14.9M	N/A	-$14.5M	-$13.3M-80.1%	-$7.4M+51.3%	-$15.2M-165.2%	-$5.7M-395.3%	-$1.2M
Investing Cash Flow	-$24.1M	-$15.9M-732.6%	-$1.9M-145.2%	$4.2M+2394.2%	-$184K-30.0%	-$141K	N/A	$7.0M	-$7.0M-90691.9%	-$8K+4.8%	-$8K	N/A	N/A
Financing Cash Flow	$40.1M	$41.0M+355.1%	$9.0M+1737.8%	-$550K-118.9%	$2.9M-65.5%	$8.4M	N/A	$1.4M	$5.5M-76.1%	$23.0M+256.8%	$6.4M	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$180	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$4.5M-111.8%	-$2.1M+0.9%	-$2.1M-95.0%	-$1.1M+30.9%	-$1.6M+30.0%	-$2.3M-26.1%	-$1.8M-22.1%	-$1.5M
Investing Cash Flow	-$8.5M+39.6%	-$14.1M-4735.7%	-$291K+76.0%	-$1.2M-297.9%	-$305K+69.7%	-$1.0M+19.4%	-$1.3M	N/A
Financing Cash Flow	-$132K+95.9%	-$3.3M-108.0%	$40.9M+1464.4%	$2.6M+248.4%	$750K-81.5%	$4.1M+22.4%	$3.3M+188.6%	$1.1M

Not reported in any period shown, so not listed: Dividends Paid.

No annual filing on record for: FY2019.

QLGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

QLGN annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Gross Margin	N/A	N/A	N/A	N/A	12.2%-2.4pp	14.6%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-296.2%	-400.8%	N/A	-195.1%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-374.0%	-316.6%	-474.2%	-182.3%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-60.7%+172.9pp	-233.6%	N/A	-257.6%-149.6pp	-108.0%+3.6pp	-111.6%	N/A	-179.7%-140.6pp	-39.1%+405.3pp	-444.4%-384.6pp	-59.8%	N/A
Return on Assets	-54.2%+79.3pp	-133.6%	N/A	-97.7%-19.3pp	-78.4%-8.3pp	-70.1%	-272.4%	-110.1%-75.7pp	-34.4%+219.6pp	-254.0%-199.3pp	-54.8%+28.7pp	-83.5%
Current Ratio	9.30+7.0x	2.33+2.1x	0.28-1.0x	1.26-3.2x	4.49+1.8x	2.71	0.30	2.57-5.8x	8.42+6.1x	2.30-9.5x	11.82+9.6x	2.23
Debt-to-Equity	0.12-0.6x	0.75	N/A	1.43+1.0x	0.38+0.4x	0.01	N/A	0.63+0.5x	0.13-0.6x	0.75+0.7x	0.09	N/A
FCF Margin	N/A	N/A	N/A	-269.1%	-262.9%	N/A	-261.2%	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Return on Equity	-27.8%	N/A	-5.3%	N/A	-7986.3%	N/A	N/A	N/A
Return on Assets	-25.4%	N/A	-4.7%+37.8pp	-42.5%+50.4pp	-92.9%	N/A	-77.6%+217.5pp	-295.0%
Current Ratio	11.57+2.3x	9.30+0.5x	8.83+8.1x	0.71-0.3x	1.01-1.3x	2.33+1.8x	0.52+0.4x	0.11
Debt-to-Equity	0.090.0x	0.120.0x	0.13	N/A	84.94+84.2x	0.75	N/A	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

No annual filing on record for: FY2019.

Similar Companies

Galecto Inc. GLTO

$1.7B

Silexion Therapeutics Corp SLXN

$2.2M

Biodexa Pharmaceuticals plc BDRX

$1.3M

Unity Btech UBX

$5.1M

Entero Therapeutics ENTO

$10.1M

Where Qualigen Therapeutics Inc Ranks

Frequently Asked Questions

Is Qualigen Therapeutics Inc profitable?

No, Qualigen Therapeutics Inc (QLGN) reported a net income of -$17.0M in fiscal year 2025.

What is Qualigen Therapeutics Inc's return on equity (ROE)?

Qualigen Therapeutics Inc (QLGN) has a return on equity of -60.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Qualigen Therapeutics Inc's operating cash flow?

Qualigen Therapeutics Inc (QLGN) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Qualigen Therapeutics Inc's total assets?

Qualigen Therapeutics Inc (QLGN) had $31.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Qualigen Therapeutics Inc spend on research and development?

Qualigen Therapeutics Inc (QLGN) invested $185K in research and development during fiscal year 2025.

How many shares does Qualigen Therapeutics Inc have outstanding?

Qualigen Therapeutics Inc (QLGN) had 5M shares outstanding as of fiscal year 2025.

What is Qualigen Therapeutics Inc's current ratio?

Qualigen Therapeutics Inc (QLGN) had a current ratio of 9.30 as of fiscal year 2025, which is generally considered healthy.

What is Qualigen Therapeutics Inc's debt-to-equity ratio?

Qualigen Therapeutics Inc (QLGN) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Qualigen Therapeutics Inc's return on assets (ROA)?

Qualigen Therapeutics Inc (QLGN) had a return on assets of -54.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Qualigen Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Qualigen Therapeutics Inc (QLGN) had $19.3M in cash against an annual operating cash burn of $7.0M. This gives an estimated cash runway of approximately 33 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Qualigen Therapeutics Inc's Piotroski F-Score?

Qualigen Therapeutics Inc (QLGN) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Qualigen Therapeutics Inc's earnings high quality?

Qualigen Therapeutics Inc (QLGN) reported a net loss of $17.0M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Qualigen Therapeutics Inc cover its interest payments?

Qualigen Therapeutics Inc (QLGN) reported an operating loss of $13.2M against $989K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.